Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different phenotypes of
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to review the
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your thoughts about
Reducing barriers to care for those with Li-Fraumeni syndrome
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and
Whole Body MRI Anxiety
A unique aspect of the LFSA International Symposium is the intersection of LFS families among globally renowned medical and
Another survey opportunity: Risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome
Another invitation to participate in a study about the risk-reducing mastectomy decision making process for adolescents and young adults
Jenn Perry on WEEI for Jimmy Fund Telethon
LFSA founder Jenn Perry shares her family's LFS story and what motivates her to advocate for research and advancements
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to cancer predisposition,
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS),
Isabel
I discovered Li-Fraumeni syndrome in 2017, after breast cancer at the age of 20. The oncologist requested genetic testing, and I was fortunate to
Janaína
I lost my mother to cancer in 2018. She had two types: lung carcinoma and brain astrocytoma. They mentioned it could be genetic at the
Fernanda
I discovered LFS in 2022 after treatment for advanced breast cancer! I needed to take the test because I lost many paternal relatives to
Reginalda
I discovered the syndrome through genetic testing after battling breast cancer and undergoing bilateral mastectomy. Today, I find myself navigating new paths, undergoing screening exams.
Shirley
I discovered Li-Fraumeni syndrome one week before quadrant surgery for breast cancer. I found out about the cancer in April 2023, underwent chemotherapy, and reduced
Anna Carolina
I discovered that I have Li-Fraumeni syndrome in 2021. At the time, my mastologist asked me for a genetic test due to the extensive
